Skip to main content
. Author manuscript; available in PMC: 2021 Aug 28.
Published in final edited form as: Eur Urol. 2018 Sep 19;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036

Table 4 –

Incidence and cumulative risk of kidney cancer in Africa

Population Qualitya Numbers Crude rate ASR (W) Cumulative risk
Mauritius D2 53 4.0 4.2 0.37
Libya C6 133 2.1 2.7 0.30
Egypt C3 1740 2.1 2.4 0.26
Tunisia C6 237 2.2 2.2 0.25
France, La Reunion D2 21 2.4 2.1 0.19
Ethiopia E6 1412 1.6 2.1 0.20
Mali E6 307 1.9 1.9 0.15
Eritrea G6 77 1.4 1.9 0.18
Somalia G6 131 1.3 1.8 0.17
Algeria C6 454 1.2 1.5 0.16
Sudan F6 462 1.2 1.5 0.15
Morocco E6 451 1.4 1.5 0.15
Djibouti G6 11 1.2 1.5 0.14
South Sudan G6 117 1.1 1.4 0.13
Kenya E6 380 0.9 1.4 0.15
Zimbabwe C6 137 1.1 1.3 0.11
Uganda C6 305 0.9 1.2 0.09
Namibia D6 19 0.8 1.2 0.14
South African Republic D3 506 1.0 1.2 0.13
Senegal G6 134 1.0 1.1 0.09
Niger E6 92 0.6 1.0 0.12
Benin F6 77 0.8 1.0 0.09
Chad G6 89 0.8 0.9 0.09
Western Sahara G6 5 0.9 0.9 0.06
Angola G6 109 0.5 0.8 0.08
Central African Republic G6 34 0.7 0.8 0.07
Madagascar G6 139 0.6 0.8 0.07
Botswana D6 12 0.6 0.8 0.10
Gabon F6 12 0.8 0.8 0.05
Zambia E6 80 0.6 0.7 0.07
Burundi G6 44 0.5 0.7 0.05
Rwanda F6 60 0.5 0.7 0.05
Malawi C6 132 0.8 0.7 0.04
Ghana F6 173 0.7 0.7 0.05
Mauritania G6 23 0.6 0.7 0.05
Cote d’Ivoire F6 127 0.6 0.7 0.06
Nigeria E6 936 0.6 0.6 0.05
Togo F6 36 0.6 0.6 0.06
Congo, Democratic G6 337 0.5 0.6 0.04
Republic of Cameroon E6 116 0.6 0.5 0.04
Burkina Faso F6 70 0.4 0.5 0.05
Congo, Republic of E6 21 0.5 0.5 0.03
Sierra Leone G6 24 0.4 0.4 0.04
Lesotho G6 6 0.3 0.4 0.03
Liberia G6 14 0.3 0.3 0.03
Equatorial Guinea G6 3 0.4 0.3 0.02
Guinea E6 27 0.3 0.3 0.03
Guinea-Bissau G6 5 0.3 0.3 0.02
Tanzania E6 106 0.2 0.2 0.01
Swaziland D6 2 0.2 0.2 0.02
Mozambique E6 34 0.1 0.1 0.00
Comoros G6 1 0.1 0.1 0.00
The Gambia D6 0 0.0 0.0 0.00
Cape Verde G6 0 0.0 0.0 0.00

ASR = age-standardised rate.

Data are sorted by ASRs. Numbers are expressed per 100 000 people. Reproduced with permission from the International Agency for Research on Cancer [3].

a

For Quality legend, please refer to the Supplementary material (Level of availability of incidence and mortality data).